目的 探讨EZH2(enhancer of zeste homolog 2)基因在肿瘤分期和淋巴结转移中的临床意义.方法 以50例癌旁肠壁组织(距肿瘤5 cm以上)作为对照组,50例结直肠癌组织作为实验组,用RT-PCR技术分析EZH2基因在结直肠癌及癌旁中的表达情况.结果 (1)EZH2在癌旁组织中的表达阳性率为12%(6/50),而在结直肠癌组织中表达阳性率为84%(42/50),两组比较差异有统计学意义(X~2=49.05,P<0.05);(2)属Dukes A、B期的9例呈EZH2阳性表达,阳性率52.94%(9/17),属Dukes C、D期的33例全部为EZH2阳性表达,阳性率100%(33/33);两组比较差异有统计学意义(X~2=15.15,P<0.005);(3)无淋巴结转移的24例中有17例呈EZH2阳性表达,阳性率为70.83%(17/24);有淋巴结转移的26例中25例呈阳性表达,阳性率为96.15%(25/26); 两组比较差异有统计学意义(X~2=4.219,P<0.05).结论 EZH2基因的表达对判断结直肠肿瘤的转移机制以及病情进展有一定的临床价值,并提示EZH2基因与肿瘤的侵袭和转移有关.
Objective To Analyze the expression of EZH2 in colorectal cancer and its clinical significance in colorectal cancer cell differentiation, staging and metastasis. Methods Fifty tissue specimens of colorectal cancer and their adjacent normal tissue specimens (more than 5 cm from the tumor) were assigned as experimental group and control group, respectively. RT-PCR was used for analysis of EZH2 expression. Results (1)The rates of EZH2 expression were 12%(6/50) and 85%(42/50) in control group and experimental group, respectively (X~2 = 49.05, P<0.005). (2)In 17 cases of Dukes stage A and B, positive expression rate of EZH2 was 52.94% (9/17), while it was 100% (33/33) in cases of Duke C and D(X~2=15.15,P<0.005).(3)The rates of EZH2 expression wese 96.15%(25/26) and 70.83(17/24) in cases with and without mesenteric lymph node gene can be applied for determining the progression of colorectal cancer. Furthermore, the EZH2 may involve in the invasion and metastasis of cancer cell.